Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 29, 2000

View Archived Issues

Penwest successfully completes phase II trials of controlled-release oxymorphone

Pharmacopeia achieves second milestone in collaboration with Schering-Plough

3-D and BMS modify drug discovery alliance

Reformulated sampatrilat shows improved bioavailability in animal model

GlycoDesign and NRC establish infectious disease research program

Genta's anti-androgen compounds inhibit prostate cancer

Sumitomo licenses class of DACH platinum compounds to Aronex

Arena's CART-derived 5-HT2A receptor inverse agonists protected by several patents

Schering AG's Mirena approved by FDA

Vernalis expands frovatriptan collaboration with Elan; company to buy out royalties from SB

XTL Biopharmaceuticals updates hepatitis programs

EMEA warns of reports of tuberculosis in patients treated with Remicade

Corixa/Coulter merger complete

Lion Bioscience to acquire Trega Biosciences in 2001

Neurocrine Biosciences' CRF1 and CRF antagonists move towards clinical evaluation

Abgenix's ABX-IL-8 enters phase II evaluation for rheumatoid arthritis

Gilead's NX-211 enters phase II for second cancer indication

NDA submitted to FDA for rapidly disintegrating desloratadine tablets

Glaxo Wellcome receives E.U. approval for Seretide MDI for the treatment of asthma

Mitsubishi Chemical reveals unique compound with potential for treatment of inflammatory disorders

Chemokine receptor antagonists claimed by Takeda

PDE4 inhibitors from Merck Frosst

Compounds active against Plasmodium and cancer cells revealed by ANU

Glucagon antagonists jointly claimed by Novo Nordisk and Agouron

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...